1. Home
  2. HBB vs ACIU Comparison

HBB vs ACIU Comparison

Compare HBB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$22.09

Market Cap

252.9M

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.22

Market Cap

221.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
ACIU
Founded
1904
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
221.9M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
HBB
ACIU
Price
$22.09
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
41.3K
235.1K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
2.38%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$606,852,000.00
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$83.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$2.03
52 Week High
$25.05
$4.00

Technical Indicators

Market Signals
Indicator
HBB
ACIU
Relative Strength Index (RSI) 53.01 39.61
Support Level $18.15 $2.13
Resistance Level $24.44 $2.66
Average True Range (ATR) 1.38 0.12
MACD -0.07 -0.01
Stochastic Oscillator 43.04 17.00

Price Performance

Historical Comparison
HBB
ACIU

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: